Company: AGIO
Filing Date: 2025-06-18
Form Type: 8-K
Source: 0001193125-25-142745
Chunk: 0

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-06-18
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02.      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

At the 2025 Annual Meeting of Stockholders of Agios Pharmaceuticals, Inc. (the “ Company”) held on June 18, 2025 (the “ Annual Meeting”), the Company’s stockholders approved an amendment (the “2023 Plan Amendment”) to the Agios Pharmaceuticals, Inc. 2023 Stock Incentive Plan (the “ Current Plan”). The 2023 Plan Amendment, which had previously been adopted by the Company’s board of directors (the “ Board”) subject to stockholder approval, increases the number of shares of common stock of the Company available for issuance under the Current Plan by 2,500,000 shares and increases the number of shares of common stock of the Company that may be issued as incentive stock options by the same number.

The description of the Current Plan, as amended by the 2023 Plan Amendment, contained on pages 87 to 100 of the Company’sdefinitive proxy statementfor the Annual Meeting, filed with the Securities and Exchange Commission (the “ SEC”) on April 25, 2025, is incorporated herein by reference. A complete copy of the Agios Pharmaceuticals, Inc. 2023 Stock Incentive Plan, as amended, is attached hereto as Exhibit 99.1 and is incorporated herein by reference.